Lang Li

FDA

1 appearance in the program

Sessions & presentations

PS51: Leveraging Duration of Response: Enhancing Efficiency in Treatment Effect Quantification and Predictability for Go/No-Go Decisions in Oncology Trials

Presentation: FDA's pooled analysis of correlation between the Restricted Mean Duration of Response (RMDoR) and long-term clinical endpoints in non-small cell lung cancer (NSCLC)

Parallel · Fri, Sep 26 , 2:50 PM

Presenting Author